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Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed in people
with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription
is associated with COVID-19, when compared with an active comparator. We per-
formed a propensity-score-matched cohort study with active comparators and a neg-
ative control outcome in a large UK-based primary care dataset. Participants
prescribed SGLT2 inhibitors (n = 9948) and a comparator group prescribed dipeptidyl
peptidase-4 (DPP-4) inhibitors (n = 14 917) were followed up from January 30 to July
27, 2020. The primary outcome was confirmed or clinically suspected COVID-19.
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The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2
inhibitors and 24.7/1000 person-years among propensity-score-matched users of
DPP-4 inhibitors. The adjusted hazard ratio was 0.92 (95% confidence interval 0.66
to 1.29), and there was no evidence of residual confounding in the negative control
analysis. We did not observe an increased risk of COVID-19 in primary care amongst
those prescribed SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting that cli-
nicians may safely use these agents in the everyday care of people with type 2 diabe-
tes during the COVID-19 pandemic.
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1 | INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was
first reported in December 2019 in the district of Wuhan, China. The
consequent multi-system illness, COVID-19, was particularly severe in
older adults and those with comorbidities,1 including diabetes.2 The
potential impact of drugs commonly used in diabetes on susceptibility
to SARS-CoV-2 infection is of significant clinical and public health
interest.3,4
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have an
established beneficial impact on cardiovascular risk, blood pressure,
chronic kidney disease progression and body weight.5 They are asso-
ciated with promotion of ACE2 activity, which may facilitate viral
entry into cells, thereby increasing the susceptibility to clinically evi-
dent disease. They may also however provide a degree of protection
via favourable impact on glycaemic control and inflammation.6 Given
the adverse outcomes associated with COVID-19 in the context of
diabetes, and the uncertainty surrounding underlying mechanisms, an
investigation of the potential for these commonly prescribed medica-
tions to influence presentation and course of COVID-19 is of
importance.
Current practice guidelines and expert opinion recommend that
SGLT2 inhibitor treatment is discontinued in the community during
acute illness and on hospital admission due to the increased risk of
diabetic ketoacidosis.7,8 However, there is currently no empirical evi-
dence that use of SGLT2 inhibitors increases the risk of developing
COVID-19 among people with type 2 diabetes in the primary care
setting.
We aimed to investigate the risk of a composite of confirmed or
suspected COVID-19 in people with type 2 diabetes prescribed
SGLT2 inhibitors compared to a propensity-score-matched cohort of
individuals prescribed a dipeptidyl peptidase-4 (DPP-4) inhibitor as an
active comparator in primary care.
2 | MATERIALS AND METHODS
Further methodological detail can be found in Appendix S1.
2.1 Study design
We conducted a population-based retrospective cohort study in
people with type 2 diabetes, comparing users of SGLT2 inhibitors
to propensity score-matched users of DPP-4 inhibitors. Data for
this cohort study were derived from The Health Improvement Net-
work (THIN), a database of routinely collected primary care records
which is generalizable to the UK population. In 2020, it included
data from 365 practices with approximately 2.1 million active adult
patients. To improve data quality, general practices were eligible to
be included in this study 12 months after the installation of Vision
software and 12 months after reporting acceptable mortality
rates.9
2.2 Study population
Individuals aged ≥18 years with a diagnosis of type 2 diabetes and
registered with an eligible general practice for ≥1 year on the
index date (January 30, 2020) were included. Patients diagnosed
with diabetes before the age of 12 years, with a record of type
1 diabetes, pancreatitis, adverse reaction to antidiabetic agents at
any time point, or pregnancy in the preceding year, were
excluded.
2.3 Exposure
Current users of SGLT2 or DPP-4 inhibitors were defined as individ-
uals with a record of prescription lasting beyond the index date.
People with type 2 diabetes with a current prescription of SGLT2
inhibitors (exposed group) were compared to individuals with a cur-
rent prescription of DPP-4 inhibitors (comparator group). Neither
cohort had a current prescription of the comparator medication.
DPP-4 inhibitors were chosen as they are safe in the long-term man-
agement of people with diabetes,10 and are actively recommended as
a first intensification step.11 Exposed and comparator groups were
mutually exclusive.
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2.4 Matching
On the index date, participants in the exposed group were
propensity-score-matched to participants in the comparator group.
Propensity score for use of SGLT2 inhibitors was estimated using a
logistic regression model including a set of covariates described in the
covariates section below.
2.5 Follow-up period
Participants were followed up from January 30, 2020 (index date)
until the earliest of the following dates: date of the outcome, death,
patient left practice, practice ceased contributing to the database, or
study end date (July 22, 2020).
2.6 Outcomes
The primary outcome was a composite of confirmed or suspected
diagnosis of COVID-19. Secondary outcomes were confirmed diag-
nosis of COVID-19 and COVID-19-related death. COVID-
19-related death was defined as a death date not later than 28 days
after occurrence of the primary outcome. We used a negative con-
trol outcome, incident back pain, during follow-up to assess the
possibility of surveillance bias and unobserved confounding.12 All
outcomes were defined using the relevant clinical (Read) codes
(Table S1).
2.7 Covariates
Covariates included: sociodemographic characteristics; lifestyle and
metabolic profile; presence of comorbid conditions; comorbid condi-
tions identified as risk factors for COVID-19; diabetes-specific condi-
tions or measures indicating diabetes severity; diabetes duration; and
history of prescriptions of relevant drugs. For a full list of covariates,
please see Appendix S1.
2.8 Statistical analysis
Crude incidence rates per 1000 person-years of COVID-19 and the
negative control outcome, back pain, were estimated for the
exposed and the comparator cohort. A Cox proportional hazards
regression model was used to determine crude and adjusted hazard
ratios (HRs) for SGLT2 inhibitor compared to DPP-4 inhibitor treat-
ment for the COVID-19 outcome and the negative control outcome.
Survival curves for the exposed and the unexposed groups were
generated for the unmatched and the propensity-score-matched
cohorts.
3 | RESULTS
A total of 9948 eligible people with type 2 diabetes with a current
prescription for SGLT2 inhibitors, and 14 917 people with a current
prescription for DPP-4 inhibitors were identified.
3.1.1. | Baseline characteristics
In the unmatched cohort, the SGLT2 inhibitor cohort was younger,
comprised a greater proportion of men, had a higher mean body mass
index, a higher proportion of current smokers and a higher prevalence
of excess alcohol use than the DPP-4 inhibitor cohort (Table S4).
The SGLT2 inhibitor cohort had a lower prevalence of com-
orbidities compared to the DPP-4 inhibitor cohort (Table S4). The
cohorts had a similar mean duration of diabetes and prevalence of dia-
betes complications (Table S4).
The proportion of the SGLT2 inhibitor cohort that had previously
used a DPP-4 inhibitor was 36.8%, and 9.1% of the DPP-4 inhibitor
cohort had previously used an SGLT2 inhibitor, prior to the washout
period (Table S4)
Following 1:1 propensity-score matching, 7676 eligible individ-
uals prescribed SGLT2 inhibitors were compared to 7676 matched
individuals prescribed DPP-4 inhibitors. After matching, the character-
istics of the DPP-4 inhibitor and SGLT2 inhibitor cohorts, including
demographic and behavioural risk factors, diabetes duration, diabetes
complications, comorbidities, metabolic profile, and prior prescrip-
tions, were similar (Table 1).
3.1.2. | Main analysis
In the unmatched cohort, after adjusting for potential confounders, no
statistically significant difference in the risk of primary care consulta-
tions for a composite of confirmed or suspected COVID-19 (adjusted
hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.64–1.16) or
confirmed COVID-19 (adjusted HR 0.66, 95% CI 0.35– 1.23; Figure 1)
was observed in the SGLT2 inhibitor compared to the DPP-4 inhibitor
cohort. During the same period, in the unmatched group the crude
incidence rate for developing back pain (negative control) was 10.7
per 1000 person-years in the exposed group compared to 8.8 per
1000 person-years in the comparator group. This translated to an
adjusted HR of 1.11 (95% CI 0.72–1.72; Table S5).
Following propensity-score matching, 69 individuals in the
exposed group (current SGLT2 inhibitor users only) and 72 individuals
in the comparator group (current DPP-4 inhibitor users only) were
diagnosed with a composite of confirmed or suspected COVID-19,
corresponding to crude incidence rates of 19.1 and 19.9 per 1000
person-years, respectively (Table S5; Figure S1). There were 15 indi-
viduals with a record of confirmed COVID-19 and one COVID-
19-related death in the exposed group and 18 individuals with a
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TABLE 1 Baseline demographic characteristics and behavioural risk factors, diabetes complications and comorbidities, metabolic




DPP-4 inhibitor users (n = 7676) SGLT2 inhibitor users (n = 7676)
Mean (SD) age, years 62.6 (10.4) 60.6 (10.8) <0.001
Men, n (%) 4777 (62.2) 4812 (62.7) 0.57
Mean (SD) BMI, kg/m2 32.2 (6.5) 33.0(6.7) <0.001
Smoking status, n (%) 0.58
Non-smokers 3776 (49.2) 3816 (50.3)
Ex-smokers 2724 (35.5) 2676 (34.9)
Current smokers 1158 (15.1) 1121 (14.6)
Missing 18 (0.2) 18 (0.2)
Excessive alcohol use, n (%) 433 (5.6) 472 (6.1) 0.19
Mean (SD) diabetes duration,years 10.6 (6.2) 10.3 (6.3) 0.001
Diabetes complications, n (%)
Peripheral neuropathy 456 (5.9) 476 (6.2) 0.52
Diabetic foot disease 272 (3.5) 272 (3.5) 1.00
Sight threating retinopathy 773 (10.1) 864 (11.3) 0.02
Baseline diabetes complications and comorbidities
Comorbidities, n (%)
Ischaemic heart disease 1242 (16.2) 1225 (16.0) 0.73
Stroke/TIA 438 (5.7) 429 (5.6) 0.78
Heart failure 291 (3.8) 276 (3.6) 0.55
Peripheral vascular disease 227 (3.0) 219 (2.9) 0.74
Atrial fibrillation 407 (5.3) 375 (4.9) 0.26
Rheumatoid arthritis 112 (1.5) 101 (1.3) 0.49
Hypertension 4267 (55.6) 4171 (54.3) 0.12
Liver disease 452 (5.8) 511 (6.7) 0.01
Chronic kidney disease 660 (8.6) 590 (7.7) 0.04
Cancersa 671 (8.7) 612 (8.0) 0.09
Blood and bone marrow cancer 90 (1.2) 80 (1.0) 0.49
Chronic respiratory disease 553 (7.2) 505 (6.6) 0.13
Baseline metabolic characteristics
Diastolic BP, n (%) 0.28
<90 mmHg 7087 (92.3) 7035 (91.6)
≥90 mmHg 583 (7.6) 633 (8.2)
Missing 6 (0.1) 8 (0.1)
Systolic BP, n (%) 0.03
<140 mmHg 5613 (73.1) 5754 (75.0)
≥140 mmHg 2057 (26.8) 1914 (24.9)
Missing, n (%) 6 (0.1) 8 (0.1)
Total cholesterol, n (%) <0.001
<5.2 mmol/L 6431 (83.8) 6208 (80.9)
5.2–6.2 mmol/L 848 (11.0) 964 (12.6)
≥6.2 mmol/L 362 (4.7) 470 (6.1)
Missing 35 (0.5) 34 (0.4)
eGFR, n (%) 0.11
<30 mL/min/1.73m2 22 (0.3) 9 (0.1)
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record of confirmed COVID-19 and four COVID-19-related deaths in
the comparator group (current DPP-4 inhibitor users only).
No statistically significant difference in risk of primary care con-
sultation for a composite of confirmed or suspected COVID-19
(adjusted HR 0.92, 95% CI 0.66– 1.29) or confirmed COVID-19
(adjusted HR 0.78, 95% CI 0.39–1.56; Figure 1) was observed in the
SGLT2 inhibitor compared to the DPP-4 inhibitor cohort. When





DPP-4 inhibitor users (n = 7676) SGLT2 inhibitor users (n = 7676)
30 to <60 mL/min/1.73m2 518 (6.7) 538 (7.0)
≥60 mL/min/1.73m2 7109 (92.6) 7098 (92.5)
Missing, n (%) 27 (0.4) 31 (0.4)
HbA1c, n (%) <0.001
<48 mmol/mol 598 (7.8) 530 (6.9)
48–57.9 mmol/mol 2121 (27.6) 1909 (24.9)
≥58 mmol/mol 4851 (63.2) 5144 (67.0)
Missing 106 (1.4) 93 (1.2)
Baseline medications used prior to index date, n (%)
DPP-4 inhibitors 7676 (100) 2443 (31.8)b <0.001
SGLT2 inhibitors 959 (12.5)b 7676 (100) <0.001
Metformin 7517 (98.0) 7519 (98.0) 1.00
Glucagon-like peptide-1 762 (9.9) 970 (12.6) <0.001
Insulin 1058 (13.8) 1328 (17.3) <0.001
Thiazolidinediones 1150 (15.0) 1188 (15.5) 0.41
Sulphonyureas 4236 (55.2) 4241 (55.3) 0.95
ACE inhibitors/ARBs 5281 (68.8) 5270 (68.7) 0.86
Other antihypertensives 4849 (63.2) 4754 (61.9) 0.12
Anticoagulants 753(9.8) 713 (9.3) 0.28
Antiplatelets 3427 (44.6) 3331 (43.4) 0.12
Lipid-lowering drugs 6641 (86.5) 6574 (85.6) 0.12
Immunosuppressive drugs 289 (3.8) 269 (3.5) 0.41
Systemic corticosteroids 749 (9.8) 687 (8.9) 0.09
Abbreviations: ACE, angiotensin-converting enzyme; ACR, albumin–creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood
pressure; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SGLT2, sodium-glucose co-transporter-
2; TIA, transient ischaemic attack.
aExcluding melanoma, and blood and bone marrow cancers.
bLast used ≥90 days before the index date.
F IGURE 1 Forest plot showing
hazard ratios (HRs) for suspected/
confirmed COVID-19 in individuals
prescribed sodium-glucose co-
transporter-2 (SGLT2) inhibitors
compared to those prescirbed dipeptidyl
peptidase-4 (DPP-4) inhibitors. CI,
confidence interval
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incidence rates were 11.4 and 8.6 per 1000 person-years, respec-
tively, for the exposed and comparator groups (Table S5). This related
to a non-statistically significant difference in risk between the groups
(adjusted HR 1.22, 95% CI 0.76–1.96).
Given the limited number of events for COVID-19-related death,
the HRs were not calculated.
4 | DISCUSSION
This is the first study to explore the relationship between SGLT2
inhibitor use and the risk of developing COVID-19. After adjusting for
a number of potential confounders, and accounting for confounding
by indication bias, we found no significant association between use of
SGLT2 inhibitors and primary care consultation for confirmed or
suspected COVID-19 infection, when compared to use of DPP-4
inhibitors in a large primary care cohort of people with type
2 diabetes.
Type 2 diabetes has been identified as a predictor of severe
COVID-19, and poor glycaemic control is associated with increased
risk of severe COVID-19 and mortality.2,13 However, information
regarding which specific glucose-lowering agents can be used to
safely maintain or improve glycaemic control in the midst of the
COVID-19 pandemic is currently limited.14 The present study found
no evidence that SGLT2 inhibitors alter the risk of developing COVID-
19. This helps to provide reassurance that these drugs can be used
safely in primary care.
There have been case reports of people with diabetes and
COVID-19 presenting with euglycaemic ketoacidosis. SGLT2 inhibi-
tors selectively reduce interstitial volume and may exert anti-
inflammatory effects,15 which could further influence outcomes from
COVID-19. The current recommendation of stopping SGLT2 inhibitor
treatment when admitted to hospital should therefore still be
followed in people with type 2 diabetes and COVID-19.
The present study has a number of limitations. Data quality is reli-
ant on the coding practices of primary care clinicians and administra-
tors. Individuals who present to primary care are more likely to be
symptomatic rather than asymptomatic, and this latter group is likely
therefore to be underrepresented. We did not have access to data on
hospitalization, inpatient management, ethnicity or socio-economic
status. In addition, there was a relatively small number of outcome
events.
The study also has some important strengths. We attempted to
minimize the effect of the differences in baseline characteristics
between groups, as well as confounding by indication bias, by using a
propensity-score-matched design. Levels of missingness were low.
This resulted in robust comparisons of similar individuals in the pri-
mary analysis. We adjusted for a large number of potential con-
founders, with analyses repeated using a negative control. This study
adds to the understanding of COVID-19 management in the primary
care setting.
Our findings show no evidence that SGLT2 inhibitor use influ-
ences susceptibility to developing COVID-19 among people with type
2 diabetes in the primary care setting. These results are reassuring
and suggest that clinicians can use these agents to improve glycaemic
control in people with type 2 diabetes in the primary care setting dur-
ing the COVID-19 pandemic, particularly given that hyperglycaemia is
a poor prognostic outcome of COVID-19.
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